Most Popular
-
1
NewJeans to terminate contract with Ador
-
2
Korean Air gets European nod to become Northeast Asia’s largest airline
-
3
NewJeans terminates contract with Ador, embarks on new journey
-
4
Ador claims exclusive contracts with NewJeans still valid
-
5
Firefighter holds truck driver for 45 minutes to save him from falling off bridge
-
6
Heavy, wet snow to fall more often this winter
-
7
SNU professors join growing movement calling for Yoon's resignation
-
8
Presidential office criticizes opposition-led state auditor, prosecutor impeachment motions
-
9
Seoul to explore supporting children born outside of marriage: Yoon's office
-
10
N. Korea launches 32nd wave of trash balloons, anti-S. Korea leaflets
Chong Kun Dang wins first overseas approval for phase 3 trial of COVID-19 treatment
By Shim Woo-hyunPublished : Sept. 30, 2021 - 17:39
Drugmaker Chong Kun Dang said Thursday that it has received an approval from the Ministry of Health of Ukraine to conduct a phase 3 clinical trial of their COVID-19 treatment candidate, Nafabeltan.
Ukraine is the first foreign country to authorize the final-stage trial of the South Korean pharmaceutical company’s self-developed COVID-19 treatment.
In Korea, Chong Kun Dang received an approval from the Ministry of Food and Drug Safety in April.
Ukraine is one of the seven foreign countries that the firm is planning to run the test in, with the others being Brazil, India, Thailand, Russia, Argentina, and Peru.
Chong Kun Dang will evaluate efficacy and safety of Nafabeltan through double-blind studies with a total of 600 COVID-19 patients at high risk for progression to severe COVID-19 cases.
Nafabeltan inhibits the activity of the spike protein of COVID-19. The company expects the treatment candidate to be effective against the existing COVID-19 variants, including the delta and lambda variants.
